MET amplifications were detected only in 14 cases (2% of those tested) in our series, a percentage consistently low considering that MET amplifications have been extensively documented as a mechanism of acquired resistance in 5–22% EGFR-mutated NSCLC upon therapeutic pressure with EGFR-TKIs; in addition, only two of these amplifications co-occurred with EGFR mutations, and thus, in patients subsequently treated with TKIs [24]. Here, MET is linked to non-small cell lung carcinoma.